Dr. Moody is a process-oriented drug developer and executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Dr. Moody has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated research organization focused on drug discovery and development for pathways of aging. R&D initiatives that constitute Ichor's portfolio companies span enzyme therapy (Lysoclear, Inc.), senolytics (FoxBio, Inc.), small molecule drug discovery (Antoxerene, Inc.), antibody mimetics (Auctus Biologics, Inc.), contract research services (Icaria Life Sciences, Inc. and Woodland Biosciences, Inc.) and a strategic investment fund (Grapeseed.Bio).